Develops first-in-class precision-medicine therapeutics targeting metabolic dysfunction and fibro-inflammation in cardiorenal metabolic diseases (obesity, heart failure, NASH/MASH, chronic kidney disease). Leverages validated targets from large-scale human proteo-genomics datasets.